NCT03664609 Deep Brain Stimulation (DBS) Retrospective Outcomes Study
| NCT ID | NCT03664609 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Scientific Corporation |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2019-03-12 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2019-03-12 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
Eligibility Criteria
Inclusion Criteria: * Must be previously treated with or eligible for implantation with a deep brain stimulation system Exclusion Criteria: * No Exclusion Criteria
Contact & Investigator
Natalie Bloom Lyons
STUDY DIRECTOR
Boston Scientific Neuromodulation Corporation
Frequently Asked Questions
Who can join the NCT03664609 clinical trial?
This trial is open to participants of all sexes, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03664609 currently recruiting?
Yes, NCT03664609 is actively recruiting participants. Contact the research team at BSNClinicalTrials@bsci.com for enrollment information.
Where is the NCT03664609 trial being conducted?
This trial is being conducted at Phoenix, United States, San Francisco, United States, Miami, United States, Tampa, United States and 11 additional locations.
Who is sponsoring the NCT03664609 clinical trial?
NCT03664609 is sponsored by Boston Scientific Corporation. The principal investigator is Natalie Bloom Lyons at Boston Scientific Neuromodulation Corporation. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.